Pharmaceutical Executive, Apr 1, 2008

Features

Money-Back Guarantee

By Thomas Nagle

...and other ways you never thought to sell your drugs

On-The-Job Off-Label Compliance

By Fred Eaton , Mark Scallon

Pharm Exec presents a user's guide to minimizing your company's risk areas (all 80 of them).

The Navigator: Charlotte Sibley

By Joanna Breitstein

Here's the saga of how market research, health outcomes, and dozens of other tools that connect the industry to patients came to be.

Chinese Puzzle

By Walter Armstrong

The contamination of heparin in China cast the drugmaker, its US supplier, and FDA as indifferent and incompetent. Then the story took a very strange turn...

Washington Report

Supply Chains Without Borders

By Jill Wechsler

International outsourcing carries risks for marketers and regulatory challenges for FDA

From the Editor

Molecular Fraud

By Patrick Clinton

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

Molecular Fraud

By Patrick Clinton

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

Global Report

British Biotech Blues

By Sarah Houlton

Can ceasing trade sales and finding funding help UK biotechs became an industry in their own right?

Commentary

Putting the "I" in "Team"

By Margaret-Ann Cole

Pharma is embracing the cross-functional team. But that doesn't mean that you must blend in with the sheep. Putting your best foot forward strengthens the team...and you.

Leadership

The WIIFM Initiative

By Sander A. Flaum

Everyone likes to work for a successful company. But how do you drive your initiatives to the top? Never underestimate courage and persistence.

Legal

Mind the (Tax) Gap

By Erika A. Kelton

A little-known provision in a new law rewards employees for blowing the whistle on tax fraud. Pharma should examine its tricky tax situation—and work out the issues on a global level.